运动对阿尔茨海默病患者认知和运动功能的影响:基于随机对照试验的元分析
Yuxin Gai1, Xuelian Dai2, Mengyi Qian3
1Department of Neurology, Ningbo Yinzhou No. 2 Hospital, 998 North Qianhe Road, Yinzhou District, Ningbo, 315100 Zhejiang China.
Cognitive neurodynamics
|August 27, 2025
概括
低强度有氧运动可显著改善阿尔茨海默病患者的认知和运动功能. 强力或高冲击运动的效果很小,强调了针对痴呆症的体力活动的重要性.
科学领域:
- 神经学
- 老年学
- 运动科学
背景情况:
- 阿尔茨海默病对认知和运动功能构成重大挑战.
- 作为治疗阿尔茨海默症的非药物干预措施,正在探索体力活动.
- 不同类型和强度的运动对阿尔茨海默病患者的疗效的证据各不相同.
研究的目的:
- 系统地审查身体活动对阿尔茨海默病患者认知和运动功能的影响.
- 评估不同运动方式 (有氧,强度,联合) 和强度对阿尔茨海默病患者的结果的影响.
主要方法:
- 在PubMed,EMBASE,Science Direct和Web of Science数据库中进行了全面的文献搜索,截至2024年10月.
- 包括25项随机对照试验 (RCT),涉及2213名参与者.
- 使用迷你精神状态检查 (MMSE) 和阿尔茨海默病评估尺度-认知子尺度 (ADAS-cog) 评估认知功能.
- 使用定时启动和启动测试 (TUG) 和6分钟步行测试 (6MWT) 评估运动功能.
主要成果:
- 与对照组相比,体力活动,特别是有氧运动和联合运动,显著提高了MMSE得分.
- 低强度和中等强度的运动显示显著的认知效益 (MMSE),而高强度的运动则没有.
- 在6MWT中,有氧运动显著改善,表明运动功能得到改善.
- 在运动和对照组之间没有观察到TUG或ADAS-cog得分的显著差异.
结论:
- 低强度有氧运动是改善阿尔茨海默病患者认知和运动功能的有效干预措施.
- 运动的类型和强度是关键因素; 强度和高强度的运动似乎不那么有益.
- 进一步的研究应该集中在优化AD管理的运动方案上.
相关概念视频
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:30Cognitive Development During Adulthood
267
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
267
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206